LambdaBiologics provides OECD-guideline-based testing services verified under GLP standards through its innovative research platform and diverse preclinical solutions. The company ensures optimal cost efficiency and performance for its clients, supporting them in meeting submission requirements for U.S. and European regulatory agencies.
LambdaBiologics offers integrated services across all stages of drug development, utilizing cutting-edge research technologies, including alternative methods to animal testing. Various alternative testing approaches, such as toxicity evaluation, are systematically conducted according to international GLP standards, ensuring reliable data and results.
For drugs that are difficult to evaluate with conventional research platforms (e.g., immune-oncology agents, anaerobic bacteria evaluation), LambdaBiologics leverages state-of-the-art organoid-based analysis to unlock new possibilities. This advanced approach overcomes traditional limitations, enabling more precise and effective research.
With expertise and a collaborative network spanning from R&D over preclinical, clinical trials and manufacturing (GMP), Lambda Biologics provides clients with optimal solutions throughout the entire drug development process.
Partner with Lambda Biologics to access everything necessary for successful global market entry.
